Six new members join the EUCOPE network
The European Confederation of Pharmaceuticals Entrepreneurs (EUCOPE) announced the joining of six (6) new members at its quarterly Members Meeting on June 22nd following Board approval.
The new members joining EUCOPE network are: Amylyx Pharmaceuticals, Arnold&Porter, Bavarian Nordic, Laboratoire Cevidra and Urovant Sciences.
During the announcement, EUCOPE’s Secretary General Alexander Natz said, “the addition of these new members signifies the great strides we have collectively made as a network over the past 14 years. We look forward to mutually beneficial collaboration while offering access to our expertise in legal and public policy government affairs, which is critical to navigating an ever-changing European landscape of product launches and market access.”
About the new members
Amylyx is a Cambridge-based pharmaceutical company dedicated to the development of therapeutics for the treatment of neurodegenerative disorders. They incorporate unconventional approaches through strong partnerships with industry leaders, scientists, doctors and organizations.
Regarding EUCOPE Membership, Lugdivine Le Dez, Head of Patient Advocacy and Government Affairs, EMEA said: “We joined EUCOPE to make sure we are monitoring important topics of relevance to Amylyx, identifying threats and opportunities, addressing them while ensuring that the interests of small companies are well-represented in the minds of EU policymakers.”
Renowned as a powerhouse in the life sciences sector, Arnold & Porter is the “go to” law firm for global and emerging life sciences companies seeking effective solutions for their business-defining matters. Their full-service team of 200+ attorneys in the US, UK, Europe, and Asia provides comprehensive support and advocacy for life sciences companies throughout the product life cycle—from concept and human trials, through approval and launch, to post-market promotion, compliance and defense.
Alexander Roussanov, Partner at Arnold & Porter said “EUCOPE is a well-established and prominent trade association in the EU that fosters genuine discussion and cooperation on key and “hot” issues for the pharmaceutical industry (e.g., the EU Pharmaceutical Strategy). Arnold & Porter are very excited to be actively involved in and contribute to EUCOPE’s work in key policy and regulatory areas, including research, innovation and related incentives, market access, rare diseases, advanced therapy medicinal products, digital health, competition law and data protection.”
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. They are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe and Canada.
Regarding membership, Stephane Martin, Senior Director and Head of Rest of the World Markets said, “Bavarian Nordic is a fully integrated vaccine company focused on the development, manufacturing and commercialization of life-saving vaccines. We are committed to saving and improving lives by unlocking the power of the immune system. As a member of EUCOPE, we want to help build a Europe where our industry can contribute to protecting the lives of European patients even more.”
BridgeBio is a biotechnology company designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers.
Ruth Nasr, Head of Market Access, EMEA for BridgeBio said “We believe membership of EUCOPE will better our understanding of the evolving European healthcare landscape (legislative, regulatory & access) and give us the opportunity to shape it so patients with rare diseases can have the best possible access to our medicines.”
Laboratoire Cevidra is a French pharmaceutical company engineered to give global pharma support in accessing the French market. Part of the Destaing Participations Group, Cevidra operates as an affiliate in France combining the exploitation, the distribution, the manufacturing & importation in a single integrated continuum process
On joining EUCOPE, Justine Gallet, Business Development Manager said “Cevidra is a French pharmaceutical company and we recently joined EUCOPE to strengthen our commitment to deliver high quality products and expertise to French patients, across the challenges of the European Regulation. We are confident that this sharing of experience and knowledge will help us find solutions and valuable partnerships that will benefit all patients.”
Founded in 2017, Urovant Sciences is a biopharmaceutical company committed to advancing innovative therapies for urological care.
On joining EUCOPE, Laura Genatossio, SVP, General Manager Europe said, “Understanding and engaging in the external environment is critical for pharmaceutical companies. As a start-up in Europe, Urovant has chosen to join EUCOPE because we consider the association the best option for this, providing not just information and engagement opportunities, but also collaboration for higher impact.”
EUCOPE is elated to have these innovative companies join the network and looks forward to greater collaboration and a renewed spirit on its continued quest to drive innovation for life sciences in Europe.